Every 10-Q that RF Acquisition Corp II (RFAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RFAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RFAI filings page.
RF Acquisition Corp II is a Cayman Islands-based special purpose acquisition company focused on deep technology targets in Asia. For the three months ended June 30, 2026, it reported net income of $104,427, driven by $459,287 of interest on funds in its Trust Account, offset by $354,860 of general, administrative and operational costs. For the six-month period, net income was $198,129.
Cash held in the Trust Account was $53,530,961 at June 30, 2026, while cash outside the Trust Account was only $10,191, contributing to a working capital deficit of $1,283,103 and shareholders’ deficit of $5,308,103. After prior redemptions of 6,668,735 shares, 4,831,265 ordinary shares remain subject to possible redemption. The company has a Business Combination Agreement with Nanyang Biologics and must complete a Business Combination by August 15, 2026 or liquidate, leading management to conclude there is substantial doubt about its ability to continue as a going concern. Disclosure controls and procedures were deemed not effective due to a material weakness in internal controls.
RF Acquisition Corp II reported unaudited results for the quarter ended March 31, 2026, while continuing to pursue its planned business combination with Nanyang Biologics under the existing Business Combination Agreement.
The SPAC recorded net income of $93,702, driven by $454,296 of interest on cash held in its trust account, partly offset by $360,594 of general, administrative and operational costs. This compares with net income of $1,020,970 for the same quarter in 2025, when trust interest was higher at $1,234,208.
At March 31, 2026, cash in the trust account totaled $52,891,674, while cash outside the trust account was $34,737. Ordinary shares subject to possible redemption were 4,831,265 at a redemption value of $10.95 per share, and there were 3,512,500 non-redeemable ordinary shares outstanding as of May 7, 2026.
Management disclosed a working capital deficit of $928,243 and stated that substantial doubt exists about the company’s ability to continue as a going concern within one year, absent completion of a business combination or additional financing. The company has until August 15, 2026 to consummate a transaction, following shareholder approval of multiple monthly extensions funded by deposits of $0.03 per public share into the trust account.
RF Acquisition Corp II reported its quarterly results for the period ended September 30, 2025 and outlined key SPAC milestones. The company recorded Q3 net income of $1,056,869, driven by $1,286,531 of interest earned on funds in its trust account, offset by $229,662 of operating and formation costs. For the nine months, net income was $3,153,849 on $3,778,478 of interest income and $624,629 of costs.
Cash held in the trust account was $122,872,409 as of September 30, 2025, with 11,500,000 ordinary shares classified as redeemable at $10.68 per share. Cash outside the trust was $562,225, and working capital was $64,578. As of November 5, 2025, 15,012,500 ordinary shares were issued and outstanding.
On October 2, 2025, the company signed a Business Combination Agreement with NYB Holdings Limited (PubCo), NYB Pte. Ltd., and Nanyang Biologics Pte. Ltd., under which each company ordinary share would be exchanged for one PubCo share and each right for 1/20 of a PubCo share. A shareholder vote is scheduled to extend the SPAC deadline up to August 15, 2026, with a proposed $0.03 per public share monthly trust deposit (up to $60,000 per month). Management disclosed substantial doubt about the company’s ability to continue as a going concern.